spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  mTOR inhibitor 

 HSMN NewsFeed - 3 Mar 2023
Aadi Bioscience Announces Leadership Transition
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Feb 2022
PANTHERx(R) Rare Selected by Aadi Bioscience to Distribute FYARRO(TM) (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for Advanced Malignant Perivascular Epithelioid Cell Neoplasm (PEComa)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 3 Feb 2016
LAM Therapeutics Closes $40M in Financing and Announces Two Clinical-Stage Programs in Rare Diseases and Cancer
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Jan 2014
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme(TM) Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Oct 2013
Syndax Names Steven M. Fruchtman, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 6 Jun 2011
Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2011
FDA Approves Trial of Pathway Therapeutics, Inc. Cancer Drug; $7.5 Million Financing in Place to Advance Novel PI3K/mTOR Inhibitor Portfolio
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2011
ARIAD Announces Election to Co-Promote Ridaforolimus in Sarcoma Indication in U.S. upon Approval
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Mar 2011
Paloma Pharmaceuticals Update on Ocular Clinical and Oncology Programs
Biopharmaceuticals Ophthalmology Oncology
 HSMN NewsFeed - 18 Jan 2011
ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2010
Semafore Pharmaceuticals Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2010
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
Phase III Study Shows Novartis Drug Afinitor(R) More Than Doubles Time Without Tumor Growth in Advanced Pancreatic NET Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jun 2010
ARIAD Names Timothy P. Clackson to New Position of President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 5 May 2010
ARIAD Announces Restructuring of Its Ridaforolimus Collaboration with Merck
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 5 May 2010
Merck Acquires Development and Commercialization Rights to Investigational mTOR Inhibitor Ridaforolimus from ARIAD Pharmaceuticals, Inc.
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology
 HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 8 Jul 2009
Intellikine Completes $51 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Jun 2009
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Apr 2009
ARIAD Appoints Former Bristol-Myers Squibb Senior Executive as New Independent Member of Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Devices Interventional
 HSMN NewsFeed - 24 Mar 2009
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Mar 2009
Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Feb 2009
Novogen to Focus on Oncology Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 6 Jan 2009
ARIAD Expands Management Team with Executive Appointments in Regulatory Affairs, Manufacturing and Information Technology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2008
Myriad Genetics Launches Sixth Personalized Medicine Product, Prezeon -- to Reveal PTEN Status
Diagnostics Oncology
 HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Oct 2008
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 31 May 2008
New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2008
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Apr 2008
Elixir Medical Announces Positive Nine-Month Results From the Excella Novolimus-Eluting Coronary Stent System First-In-Man Study
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Feb 2008
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2007
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents
Devices Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 21 Aug 2007
Abraxis BioScience and The Scripps Research Institute Enter Exclusive Licensing Agreement for the Worldwide Development and Commercialization of a Novel Epothilone Therapeutic for the Treatment of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 1 Aug 2007
Deforolimus Approved as Nonproprietary Name for AP23573 - ARIAD's Novel mTOR Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jul 2007
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2007
ARIAD Announces Appointment of Senior Oncology Executive to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2007
ARIAD Presents Additional Efficacy Data on AP23573, Novel mTOR Inhibitor, in Phase 2 Advanced Sarcoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Data Presented at ASCO Showed TORISEL Significantly Increased Quality-Adjusted Survival for Patients With Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
FDA Approves TORISEL, a Targeted First-in-Class mTOR Inhibitor for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2007
Data Published in the New England Journal of Medicine Showed TORISEL Extended Median Overall Survival for Patients with Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2007
Wyeth Provides Update on FDA Review of the Torisel New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Feb 2007
ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 2 Nov 2006
ARIAD Presents Expanded Efficacy Data On AP23573, Novel mTOR Inhibitor, In Phase 2 Advanced Sarcoma Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2006
ARIAD Grants Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Oct 2006
Wyeth Submits NDA and MAA for Torisel for the Treatment of Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Biotica Enters into a Research and License Agreement with Wyeth for Novel Rapamycin Analogs
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Oct 2006
Kyowa Hakko Grants Keryx Biopharmaceuticals Exclusive Rights to UCN-01, a Novel, Anticancer Agent in Phase II Clinical Development
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
mTOR inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.